Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (41-50 of 162) with videos related to

Pageof 17
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|April 30, 2022
CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignanciesSamantha Bruno, Andrea Ghelli Luserna di Rorà, Roberta Napolitano, et al.
Case Reports in Hematology|September 12, 2017
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a CaseCristina Bucelli, Daniele Cattaneo, Valeria Ferla, et al.
International Journal of Molecular Sciences|June 6, 2020
Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and TherapyMargherita Martelli, Cecilia Monaldi, Sara De Santis, et al.
Leukemia Research|October 4, 2011
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinibTamara Intermesoli, Fausto Castagnetti, Simona Soverini, et al.
Oncotarget|November 21, 2017
Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemiaManuela Mancini, Simona Soverini, Gabriele Gugliotta, et al.
Molecular Cancer|May 1, 2015
Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencingJana Linhartova, Lenka Hovorkova, Simona Soverini, et al.
Hematological Oncology|July 21, 2016
What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?Matthieu Lewis, Mhairi Copland, Simona Soverini, et al.
Haematologica|July 2, 2002
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology oneGiovanni Martinelli, Marilina Amabile, Barbara Giannini, et al.
The Lancet. Oncology|March 3, 2007
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALLSimona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Frontiers in Oncology|October 15, 2019
Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the <i>Avant-Garde</i> of Molecular HematologyVlad Moisoiu, Patric Teodorescu, Lorand Parajdi, et al.
Pageof 17

Showing results (41-50 of 162) with videos related to

Sort By:
Pageof 17
Journal of Experimental & Clinical Cancer Research : CR|April 30, 2022
CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignanciesSamantha Bruno, Andrea Ghelli Luserna di Rorà, Roberta Napolitano, et al.
Case Reports in Hematology|September 12, 2017
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a CaseCristina Bucelli, Daniele Cattaneo, Valeria Ferla, et al.
International Journal of Molecular Sciences|June 6, 2020
Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and TherapyMargherita Martelli, Cecilia Monaldi, Sara De Santis, et al.
Leukemia Research|October 4, 2011
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinibTamara Intermesoli, Fausto Castagnetti, Simona Soverini, et al.
Oncotarget|November 21, 2017
Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemiaManuela Mancini, Simona Soverini, Gabriele Gugliotta, et al.
Molecular Cancer|May 1, 2015
Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencingJana Linhartova, Lenka Hovorkova, Simona Soverini, et al.
Hematological Oncology|July 21, 2016
What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?Matthieu Lewis, Mhairi Copland, Simona Soverini, et al.
Haematologica|July 2, 2002
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology oneGiovanni Martinelli, Marilina Amabile, Barbara Giannini, et al.
The Lancet. Oncology|March 3, 2007
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALLSimona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Frontiers in Oncology|October 15, 2019
Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the <i>Avant-Garde</i> of Molecular HematologyVlad Moisoiu, Patric Teodorescu, Lorand Parajdi, et al.
Pageof 17